Chugai Pharmaceutical’s Sales And Profit Drop
This article was originally published in PharmAsia News
Chugai Pharmaceutical announced drops in sales, income and consolidated net profit for the first nine months of 2008. Chugai's sales reduced by 8.3 percent to ¥229.6 billion, business income dropped by 18.8 percent to ¥39.8 billion, ordinary income reduced by 16.2 percent to ¥42.7 billion and net profit is down by 0.3 percent to ¥30.1 billion. (Click here for more - Japanese language
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.